FDA Approves Acalabrutinib (Calquence) for Mantle Cell Lymphoma FDA Approves Acalabrutinib (Calquence) for Mantle Cell Lymphoma

Acalabrutinib is a second-generation Bruton ' s tyrosine kinase inhibitor.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news